The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Results from MajesTEC-1: health-related quality of life with teclistamab in patients with R/R MM
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, shares some updates from the MajesTEC-1 trial (NCT04557098) investigating the use of teclistamab, a bispecific T-cell engager (BiTE), for the treatment of patients with relapsed/refractory (R/R) multiple myeloma. Dr Popat highlights the improved response rate and progression-free survival (PFS) observed in patients, and further discusses the improved quality of life reported in patient questionnaires. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
